1
|
Chiritescu G, Dumon K, Mercadé TM, Lang I, Vivas CS, Papai Z, Janssens J, Hendrickx K, Pracht M, Van den Eynde M, Taïeb J, Moons V, Geboes K, Van Laethem J, Greil R, Cervantes A, Vergauwe P, Ferrante M, Vanderstraeten E, Fridrik M, Wöll E, Limón M, Rivera F, Sagaert X, Tejpar S, Van Cutsem E. A two arm phase II study of FOLFIRI in combination with standard or escalating dose of cetuximab as first line treatment for metastatic colorectal cancer: Everest 2 final results. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy149.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
2
|
Rinnerthaler G, Gampenrieder SP, Petzer A, Pusch R, Fridrik M, Rossmann D, Balic M, Egle D, Rumpold H, Singer C, Bartsch R, Melchardt T, Ulmer H, Mlineritsch B, Greil R. Abstract OT2-07-11: Ixazomib in combination with carboplatin in pretreated women with advanced triple negative breast cancer, a phase I/II trial (AGMT MBC-10 trial). Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-ot2-07-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Triple-negative breast cancer (TNBC) comprises a heterogeneous group of diseases which are generally associated with a poor prognosis. Up to now, no targeted treatment beyond anti-VEGF therapy is approved for TNBC so far and cytotoxic agents are the mainstay for the treatment of advanced tumor stages. Ixazomib is a selective, and reversible inhibitor of the proteasome, which has been mainly investigated in the treatment of multiple myeloma. In a preclinical study triple-negative breast cancer cells were treated with bortezomib, a first generation proteaseome inhibitor, alone and in combination with cisplatin, which had a synergistic effect. Clinical data are available for carboplatin plus bortezomib in metastatic ovarian and lung cancers showing remarkable antitumor activity and good tolerability. Based on this rational, the MBC-10 trial will evaluate the toxicity profile and efficacy of ixazomib in combination with carboplatin in patients with advanced TNBC.
Trial Design: Patients with metastatic TNBC pretreated with at least one prior line of chemotherapy for advanced disease with a confirmed disease progression and measurable disease are eligible for this study. Patients will receive ixazomib in combination with carboplatin on days 1, 8, and 15 in a 28-day cycle. The phase I part of this study uses an alternate dose escalation accelerated titration design. After establishing the maximum tolerated dose (MTD), accrual continues to evaluate the efficacy and safety of the combination (phase II, including 41 evaluable patients). All patients will continue on study drugs until disease progression, unacceptable toxicity or discontinuation for any other reason. Primary endpoint of the phase II is overall response rate, secondary endpoints include safety profile, progression-free survival and quality of life. This trial is open for patient enrollment since November 2016 in six Austrian cancer centers. Accrual is planned to be completed within two years. ClinicalTrials.gov Identifier: NCT02993094
Citation Format: Rinnerthaler G, Gampenrieder SP, Petzer A, Pusch R, Fridrik M, Rossmann D, Balic M, Egle D, Rumpold H, Singer C, Bartsch R, Melchardt T, Ulmer H, Mlineritsch B, Greil R. Ixazomib in combination with carboplatin in pretreated women with advanced triple negative breast cancer, a phase I/II trial (AGMT MBC-10 trial) [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr OT2-07-11.
Collapse
Affiliation(s)
- G Rinnerthaler
- Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Klinikum Wels-Grieskirchen, Wels, Austria; Johannes Kepler University Linz, Linz, Austria; County Hospital Steyr, Steyr, Austria; Medical University Graz, Graz, Austria; Innsbruck Medical University, Innsbruck, Austria; General Hospital Feldkirch, Feldkirch, Austria; Cancer Comprehensive Center, Medical University of Vienna, Vienna, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - SP Gampenrieder
- Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Klinikum Wels-Grieskirchen, Wels, Austria; Johannes Kepler University Linz, Linz, Austria; County Hospital Steyr, Steyr, Austria; Medical University Graz, Graz, Austria; Innsbruck Medical University, Innsbruck, Austria; General Hospital Feldkirch, Feldkirch, Austria; Cancer Comprehensive Center, Medical University of Vienna, Vienna, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - A Petzer
- Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Klinikum Wels-Grieskirchen, Wels, Austria; Johannes Kepler University Linz, Linz, Austria; County Hospital Steyr, Steyr, Austria; Medical University Graz, Graz, Austria; Innsbruck Medical University, Innsbruck, Austria; General Hospital Feldkirch, Feldkirch, Austria; Cancer Comprehensive Center, Medical University of Vienna, Vienna, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - R Pusch
- Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Klinikum Wels-Grieskirchen, Wels, Austria; Johannes Kepler University Linz, Linz, Austria; County Hospital Steyr, Steyr, Austria; Medical University Graz, Graz, Austria; Innsbruck Medical University, Innsbruck, Austria; General Hospital Feldkirch, Feldkirch, Austria; Cancer Comprehensive Center, Medical University of Vienna, Vienna, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - M Fridrik
- Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Klinikum Wels-Grieskirchen, Wels, Austria; Johannes Kepler University Linz, Linz, Austria; County Hospital Steyr, Steyr, Austria; Medical University Graz, Graz, Austria; Innsbruck Medical University, Innsbruck, Austria; General Hospital Feldkirch, Feldkirch, Austria; Cancer Comprehensive Center, Medical University of Vienna, Vienna, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - D Rossmann
- Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Klinikum Wels-Grieskirchen, Wels, Austria; Johannes Kepler University Linz, Linz, Austria; County Hospital Steyr, Steyr, Austria; Medical University Graz, Graz, Austria; Innsbruck Medical University, Innsbruck, Austria; General Hospital Feldkirch, Feldkirch, Austria; Cancer Comprehensive Center, Medical University of Vienna, Vienna, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - M Balic
- Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Klinikum Wels-Grieskirchen, Wels, Austria; Johannes Kepler University Linz, Linz, Austria; County Hospital Steyr, Steyr, Austria; Medical University Graz, Graz, Austria; Innsbruck Medical University, Innsbruck, Austria; General Hospital Feldkirch, Feldkirch, Austria; Cancer Comprehensive Center, Medical University of Vienna, Vienna, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - D Egle
- Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Klinikum Wels-Grieskirchen, Wels, Austria; Johannes Kepler University Linz, Linz, Austria; County Hospital Steyr, Steyr, Austria; Medical University Graz, Graz, Austria; Innsbruck Medical University, Innsbruck, Austria; General Hospital Feldkirch, Feldkirch, Austria; Cancer Comprehensive Center, Medical University of Vienna, Vienna, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - H Rumpold
- Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Klinikum Wels-Grieskirchen, Wels, Austria; Johannes Kepler University Linz, Linz, Austria; County Hospital Steyr, Steyr, Austria; Medical University Graz, Graz, Austria; Innsbruck Medical University, Innsbruck, Austria; General Hospital Feldkirch, Feldkirch, Austria; Cancer Comprehensive Center, Medical University of Vienna, Vienna, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - C Singer
- Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Klinikum Wels-Grieskirchen, Wels, Austria; Johannes Kepler University Linz, Linz, Austria; County Hospital Steyr, Steyr, Austria; Medical University Graz, Graz, Austria; Innsbruck Medical University, Innsbruck, Austria; General Hospital Feldkirch, Feldkirch, Austria; Cancer Comprehensive Center, Medical University of Vienna, Vienna, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - R Bartsch
- Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Klinikum Wels-Grieskirchen, Wels, Austria; Johannes Kepler University Linz, Linz, Austria; County Hospital Steyr, Steyr, Austria; Medical University Graz, Graz, Austria; Innsbruck Medical University, Innsbruck, Austria; General Hospital Feldkirch, Feldkirch, Austria; Cancer Comprehensive Center, Medical University of Vienna, Vienna, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - T Melchardt
- Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Klinikum Wels-Grieskirchen, Wels, Austria; Johannes Kepler University Linz, Linz, Austria; County Hospital Steyr, Steyr, Austria; Medical University Graz, Graz, Austria; Innsbruck Medical University, Innsbruck, Austria; General Hospital Feldkirch, Feldkirch, Austria; Cancer Comprehensive Center, Medical University of Vienna, Vienna, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - H Ulmer
- Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Klinikum Wels-Grieskirchen, Wels, Austria; Johannes Kepler University Linz, Linz, Austria; County Hospital Steyr, Steyr, Austria; Medical University Graz, Graz, Austria; Innsbruck Medical University, Innsbruck, Austria; General Hospital Feldkirch, Feldkirch, Austria; Cancer Comprehensive Center, Medical University of Vienna, Vienna, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - B Mlineritsch
- Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Klinikum Wels-Grieskirchen, Wels, Austria; Johannes Kepler University Linz, Linz, Austria; County Hospital Steyr, Steyr, Austria; Medical University Graz, Graz, Austria; Innsbruck Medical University, Innsbruck, Austria; General Hospital Feldkirch, Feldkirch, Austria; Cancer Comprehensive Center, Medical University of Vienna, Vienna, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - R Greil
- Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Klinikum Wels-Grieskirchen, Wels, Austria; Johannes Kepler University Linz, Linz, Austria; County Hospital Steyr, Steyr, Austria; Medical University Graz, Graz, Austria; Innsbruck Medical University, Innsbruck, Austria; General Hospital Feldkirch, Feldkirch, Austria; Cancer Comprehensive Center, Medical University of Vienna, Vienna, Austria; Medical University Innsbruck, Innsbruck, Austria
| |
Collapse
|
3
|
Maschek W, Hatzl-Griesenhofer M, Huber H, Wimmer G, Wahl G, Fridrik M, Pichler R. Clinical value of FDG Hybrid-PET in staging and restaging of malignant lymphoma – compared with conventional diagnostic methods. Nuklearmedizin 2018. [DOI: 10.1055/s-0038-1632265] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Summary
Aim of the present retrospective study was to validate the clinical value of F-18-FDG PET imaging in lymphoma patients with a dual head camera modified for coincidence detection. Staging before and after oncological treatment was compared with a conservative diagnostic approach. Methods: 48 patients (28 non-Hodgkin lymphoma, 20 Hodgkin’s disease) received FDG-Hybrid-PET scans. Pretherapeutic staging was realized in 28 patients, 9 of them had control studies after they had completed therapy. Totally 29 persons were examined for posttherapeutic restaging. Computed tomography imaging and lymph node sonography was performed in all cases. Results were validated by clinical follow-up, in three cases a récidivé was proven by biopsy. Results: CT and ultrasound detected 77 lesions in 28 patients compared with 100 visualized by PET, but this difference in pretherapeutic staging did not reach significance at p >0.05 by Fisher’s t-test. Hybrid-PET obtained a sensitivity of 93%, a specifity of 79%, a positive of 82% and a negative predictive value of 92% for detection of residual disease. The values for CT + US were 87%, 64%, 72% and 88% respectively. Conclusion: FDG Hybrid-PET is as or even more accurate than standard morphologic diagnostic methods for prestaging in malignant lymphoma. Additionally, there is a substancial benefit for therapy monitoring of residual disease using coincidence detection PET with a ¾-inch crystal gamma camera.
Collapse
|
4
|
Singer CF, Tan YY, Fitzal F, Steger GG, Egle D, Reiner A, Rudas M, Gruber C, Bartsch R, Fridrik M, Seifert M, Exner R, Balic M, Bago-Horvath Z, Filipits M, Gnant M. Abstract P1-09-10: Pathological complete response to neoadjuvant trastuzumab is dependent on HER2/CEP17 ratio in HER2-amplified early breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p1-09-10] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose To evaluate whether pathological complete response to neoadjuvant trastuzumab is dependent on the level of HER2 amplification.
Patients and Methods 114 women with HER2-overexpressing early breast cancer who had received neo-adjuvant trastuzumab in the prospective ABCSG-24 and ABCSG-32 trials, and for whom the HER2/CEP17 ratio was available, were included in this analysis. The ratio was correlated with tumor response as measured by the three most commonly used definitions of pathological complete response: ypT0 ypN0, ypT0/is ypN0, and ypT0/is.
Results In trastuzumab-treated patients, ypT0 pN0 was achieved in 69.0% of patients with a HER2/CEP17 ratio of >6, but only in 30.4% of tumors with a ratio of ≤6 (p=0.001, Chi Square test). When pCR was defined by ypT0/is pN0 or by ypTis, 75.9% and 82.8% of tumors with a high ratio had a complete remission, while only 39.1%, and 38.3% with a low ratio achieved a pCR (p=0.002 and p<0.001, respectively). Logistic regression revealed that tumors with a higher HER2/CEP17 ratio had a significantly higher probability to achieve ypT0 ypN0 (OR: 5.08, 95% CI 1.86-13.90; p=0.002) than tumors with a low ratio, while none of the other clinicopathological parameters was predictive of pCR. The association between high HER2 amplification and pCR was almost exclusively confined to HR positive tumors (62.5% vs. 24.0%, 75.0% vs. 28.0%, and 87.5% vs. 28.0%, for ypT0 ypN0, ypT0/is ypN0, and ypT0/is; p=0.014, p=0.005, and p<0.001), and was largely absent in HR negative tumors.
Conclusion A HER2/CEP17 ratio of >6 in the pre-therapeutic tumor biopsy is associated with a significantly higher pCR rate particularly in HER2 / HR co-positive tumors, and can be used to predict outcome before neoadjuvant trastuzumab is initiated.
Citation Format: Singer CF, Tan YY, Fitzal F, Steger GG, Egle D, Reiner A, Rudas M, Gruber C, Bartsch R, Fridrik M, Seifert M, Exner R, Balic M, Bago-Horvath Z, Filipits M, Gnant M, For the Austrian Breast and Colorectal Cancer Study Group. Pathological complete response to neoadjuvant trastuzumab is dependent on HER2/CEP17 ratio in HER2-amplified early breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-09-10.
Collapse
Affiliation(s)
- CF Singer
- Medical University Vienna, Vienna, Austria; Cancer Comprehensive Center, Medical University Vienna, Vienna, Austria; Medical University of Innsbruck, Innsbruck, Austria; Institute of Pathology, Sozialmedizinisches Zentrum Ost, Vienna, Austria; Institute of Pathology, Medical University of Vienna, Vienna, Austria; Institute for Clinical Pathology, Barmherzige Schwestern Hospital, Linz, Austria; Allgemeines Krankenhaus Linz, Linz, Austria; Medical University of Graz, Graz, Austria; Institute of Cancer Research, Medical University of Vienna, Vienna, Austria
| | - YY Tan
- Medical University Vienna, Vienna, Austria; Cancer Comprehensive Center, Medical University Vienna, Vienna, Austria; Medical University of Innsbruck, Innsbruck, Austria; Institute of Pathology, Sozialmedizinisches Zentrum Ost, Vienna, Austria; Institute of Pathology, Medical University of Vienna, Vienna, Austria; Institute for Clinical Pathology, Barmherzige Schwestern Hospital, Linz, Austria; Allgemeines Krankenhaus Linz, Linz, Austria; Medical University of Graz, Graz, Austria; Institute of Cancer Research, Medical University of Vienna, Vienna, Austria
| | - F Fitzal
- Medical University Vienna, Vienna, Austria; Cancer Comprehensive Center, Medical University Vienna, Vienna, Austria; Medical University of Innsbruck, Innsbruck, Austria; Institute of Pathology, Sozialmedizinisches Zentrum Ost, Vienna, Austria; Institute of Pathology, Medical University of Vienna, Vienna, Austria; Institute for Clinical Pathology, Barmherzige Schwestern Hospital, Linz, Austria; Allgemeines Krankenhaus Linz, Linz, Austria; Medical University of Graz, Graz, Austria; Institute of Cancer Research, Medical University of Vienna, Vienna, Austria
| | - GG Steger
- Medical University Vienna, Vienna, Austria; Cancer Comprehensive Center, Medical University Vienna, Vienna, Austria; Medical University of Innsbruck, Innsbruck, Austria; Institute of Pathology, Sozialmedizinisches Zentrum Ost, Vienna, Austria; Institute of Pathology, Medical University of Vienna, Vienna, Austria; Institute for Clinical Pathology, Barmherzige Schwestern Hospital, Linz, Austria; Allgemeines Krankenhaus Linz, Linz, Austria; Medical University of Graz, Graz, Austria; Institute of Cancer Research, Medical University of Vienna, Vienna, Austria
| | - D Egle
- Medical University Vienna, Vienna, Austria; Cancer Comprehensive Center, Medical University Vienna, Vienna, Austria; Medical University of Innsbruck, Innsbruck, Austria; Institute of Pathology, Sozialmedizinisches Zentrum Ost, Vienna, Austria; Institute of Pathology, Medical University of Vienna, Vienna, Austria; Institute for Clinical Pathology, Barmherzige Schwestern Hospital, Linz, Austria; Allgemeines Krankenhaus Linz, Linz, Austria; Medical University of Graz, Graz, Austria; Institute of Cancer Research, Medical University of Vienna, Vienna, Austria
| | - A Reiner
- Medical University Vienna, Vienna, Austria; Cancer Comprehensive Center, Medical University Vienna, Vienna, Austria; Medical University of Innsbruck, Innsbruck, Austria; Institute of Pathology, Sozialmedizinisches Zentrum Ost, Vienna, Austria; Institute of Pathology, Medical University of Vienna, Vienna, Austria; Institute for Clinical Pathology, Barmherzige Schwestern Hospital, Linz, Austria; Allgemeines Krankenhaus Linz, Linz, Austria; Medical University of Graz, Graz, Austria; Institute of Cancer Research, Medical University of Vienna, Vienna, Austria
| | - M Rudas
- Medical University Vienna, Vienna, Austria; Cancer Comprehensive Center, Medical University Vienna, Vienna, Austria; Medical University of Innsbruck, Innsbruck, Austria; Institute of Pathology, Sozialmedizinisches Zentrum Ost, Vienna, Austria; Institute of Pathology, Medical University of Vienna, Vienna, Austria; Institute for Clinical Pathology, Barmherzige Schwestern Hospital, Linz, Austria; Allgemeines Krankenhaus Linz, Linz, Austria; Medical University of Graz, Graz, Austria; Institute of Cancer Research, Medical University of Vienna, Vienna, Austria
| | - C Gruber
- Medical University Vienna, Vienna, Austria; Cancer Comprehensive Center, Medical University Vienna, Vienna, Austria; Medical University of Innsbruck, Innsbruck, Austria; Institute of Pathology, Sozialmedizinisches Zentrum Ost, Vienna, Austria; Institute of Pathology, Medical University of Vienna, Vienna, Austria; Institute for Clinical Pathology, Barmherzige Schwestern Hospital, Linz, Austria; Allgemeines Krankenhaus Linz, Linz, Austria; Medical University of Graz, Graz, Austria; Institute of Cancer Research, Medical University of Vienna, Vienna, Austria
| | - R Bartsch
- Medical University Vienna, Vienna, Austria; Cancer Comprehensive Center, Medical University Vienna, Vienna, Austria; Medical University of Innsbruck, Innsbruck, Austria; Institute of Pathology, Sozialmedizinisches Zentrum Ost, Vienna, Austria; Institute of Pathology, Medical University of Vienna, Vienna, Austria; Institute for Clinical Pathology, Barmherzige Schwestern Hospital, Linz, Austria; Allgemeines Krankenhaus Linz, Linz, Austria; Medical University of Graz, Graz, Austria; Institute of Cancer Research, Medical University of Vienna, Vienna, Austria
| | - M Fridrik
- Medical University Vienna, Vienna, Austria; Cancer Comprehensive Center, Medical University Vienna, Vienna, Austria; Medical University of Innsbruck, Innsbruck, Austria; Institute of Pathology, Sozialmedizinisches Zentrum Ost, Vienna, Austria; Institute of Pathology, Medical University of Vienna, Vienna, Austria; Institute for Clinical Pathology, Barmherzige Schwestern Hospital, Linz, Austria; Allgemeines Krankenhaus Linz, Linz, Austria; Medical University of Graz, Graz, Austria; Institute of Cancer Research, Medical University of Vienna, Vienna, Austria
| | - M Seifert
- Medical University Vienna, Vienna, Austria; Cancer Comprehensive Center, Medical University Vienna, Vienna, Austria; Medical University of Innsbruck, Innsbruck, Austria; Institute of Pathology, Sozialmedizinisches Zentrum Ost, Vienna, Austria; Institute of Pathology, Medical University of Vienna, Vienna, Austria; Institute for Clinical Pathology, Barmherzige Schwestern Hospital, Linz, Austria; Allgemeines Krankenhaus Linz, Linz, Austria; Medical University of Graz, Graz, Austria; Institute of Cancer Research, Medical University of Vienna, Vienna, Austria
| | - R Exner
- Medical University Vienna, Vienna, Austria; Cancer Comprehensive Center, Medical University Vienna, Vienna, Austria; Medical University of Innsbruck, Innsbruck, Austria; Institute of Pathology, Sozialmedizinisches Zentrum Ost, Vienna, Austria; Institute of Pathology, Medical University of Vienna, Vienna, Austria; Institute for Clinical Pathology, Barmherzige Schwestern Hospital, Linz, Austria; Allgemeines Krankenhaus Linz, Linz, Austria; Medical University of Graz, Graz, Austria; Institute of Cancer Research, Medical University of Vienna, Vienna, Austria
| | - M Balic
- Medical University Vienna, Vienna, Austria; Cancer Comprehensive Center, Medical University Vienna, Vienna, Austria; Medical University of Innsbruck, Innsbruck, Austria; Institute of Pathology, Sozialmedizinisches Zentrum Ost, Vienna, Austria; Institute of Pathology, Medical University of Vienna, Vienna, Austria; Institute for Clinical Pathology, Barmherzige Schwestern Hospital, Linz, Austria; Allgemeines Krankenhaus Linz, Linz, Austria; Medical University of Graz, Graz, Austria; Institute of Cancer Research, Medical University of Vienna, Vienna, Austria
| | - Z Bago-Horvath
- Medical University Vienna, Vienna, Austria; Cancer Comprehensive Center, Medical University Vienna, Vienna, Austria; Medical University of Innsbruck, Innsbruck, Austria; Institute of Pathology, Sozialmedizinisches Zentrum Ost, Vienna, Austria; Institute of Pathology, Medical University of Vienna, Vienna, Austria; Institute for Clinical Pathology, Barmherzige Schwestern Hospital, Linz, Austria; Allgemeines Krankenhaus Linz, Linz, Austria; Medical University of Graz, Graz, Austria; Institute of Cancer Research, Medical University of Vienna, Vienna, Austria
| | - M Filipits
- Medical University Vienna, Vienna, Austria; Cancer Comprehensive Center, Medical University Vienna, Vienna, Austria; Medical University of Innsbruck, Innsbruck, Austria; Institute of Pathology, Sozialmedizinisches Zentrum Ost, Vienna, Austria; Institute of Pathology, Medical University of Vienna, Vienna, Austria; Institute for Clinical Pathology, Barmherzige Schwestern Hospital, Linz, Austria; Allgemeines Krankenhaus Linz, Linz, Austria; Medical University of Graz, Graz, Austria; Institute of Cancer Research, Medical University of Vienna, Vienna, Austria
| | - M Gnant
- Medical University Vienna, Vienna, Austria; Cancer Comprehensive Center, Medical University Vienna, Vienna, Austria; Medical University of Innsbruck, Innsbruck, Austria; Institute of Pathology, Sozialmedizinisches Zentrum Ost, Vienna, Austria; Institute of Pathology, Medical University of Vienna, Vienna, Austria; Institute for Clinical Pathology, Barmherzige Schwestern Hospital, Linz, Austria; Allgemeines Krankenhaus Linz, Linz, Austria; Medical University of Graz, Graz, Austria; Institute of Cancer Research, Medical University of Vienna, Vienna, Austria
| | | |
Collapse
|
5
|
Rinnerthaler G, Gampenrieder SP, Fridrik M, Petzer A, Hubalek M, Petru E, Jäger T, Andel J, Balic M, Ulmer H, Mlineritsch B, Greil R. Abstract P1-13-10: Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Stage 1 results of a phase II trial (AGMT MBC-6). Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p1-13-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Although there is no single accepted standard of care after failure of anthracycline and taxane therapy in HER2-negative metastatic breast cancer, capecitabine is a well-established treatment option. Bendamustine is a hybrid cytotoxic drug because of its structural similarity to alkylating agents and purine and it is generally well tolerated. Since bendamustine has already shown anticancer activity in breast cancer we evaluated the efficacy and tolerability of bendamustine in combination with capecitabine in 40 patients with advanced breast cancer after anthracycline and/or taxane pretreatment.
Patients and methods: MBC-6 is a non-randomized, multicenter, open-label, single-arm phase II study in patients with HER2-negative advanced breast cancer (ClinicalTrials.gov identifier: NCT01891227). All patients were pretreated with anthracyclines and/or taxans in the (neo-)adjuvant and/or metastatic setting and measurable disease according to RECIST 1.1. had to be present at baseline. Following a two-stage Green-Dahlberg design, 20 subjects were accrued and treated within stage 1 of the study. The trial was planned to enroll further 20 patients if there were at least four subjects (20%) with a complete (CR) or partial response (PR). Eligible patients received 1000 mg/m2 capecitabine twice daily on days 1 to 14 in combination with 80 mg/m2 bendamustine on day 1 and 8 of a 3-week cycle. After a maximum of eight cycles capecitabine was continued as single drug therapy until disease progression or unacceptable toxicity. The primary endpoint was overall response rate (ORR). Secondary endpoints were progression free survival (PFS), clinical benefit rate (CBR), safety profile and quality of life. Here we report the efficacy and safety analysis of stage 1 patients.
Results: From September 2013 to May 2015, 40 patients were recruited in eight Austrian centers. Median age of the stage 1 cohort was 59 years (range 29-77), 80% and 20% of patients had an ECOG performance score of 0 and 1, respectively. Thirty-three percent had triple-negative disease, 85% had had (neo-)adjuvant treatment and 65% patients were pretreated with at least one chemotherapy line for metastatic disease (15% one line, 50% two lines, 40% three lines). In stage 1, ORR was 50% with 9 confirmed PR and 1 confirmed CR, and ORR was comparable between hormone receptor-positive and triple-negative disease (54% vs. 43%). CBR was 55%. At data cut-off on 05/28/15 overall 15 of 20 patients had discontinued treatment: 10 patients (50%) due to progressive disease, 3 (15%) because of adverse events (AEs) and 2 patients on their own decision (10%). Five patients (25%) experienced at least one drug related non-hematological AE ≥ grade 3: 2 diarrhea, 2 fatigue, 3 respiratory or viral infections, 1 dyspnea, 1 thromboembolic event (each grade 3). One grade 4 hematological AE (neutropenia) was observed. One patient died as a result of restrictive cardiomyopathy, where a relationship to capecitabine cannot be excluded, but seems unlikely.
Conclusion: The combination of capecitabine and bendamustine has a moderate toxicity profile and the response data of the stage 1 are promising. Final study results are awaited in the first half of 2016.
Citation Format: Rinnerthaler G, Gampenrieder SP, Fridrik M, Petzer A, Hubalek M, Petru E, Jäger T, Andel J, Balic M, Ulmer H, Mlineritsch B, Greil R. Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Stage 1 results of a phase II trial (AGMT MBC-6). [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-13-10.
Collapse
Affiliation(s)
- G Rinnerthaler
- Salzburg Cancer Research Institute With Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria; General Hospital Linz, Linz, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Innsbruck Medical University, Innsbruck, Austria; Medical University Graz, Innsbruck, Austria; General Hospital Feldkirch, Feldkirch, Austria; County Hospital Steyr, Steyr, Austria; Division of Oncology, Medical University Graz, Graz, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - SP Gampenrieder
- Salzburg Cancer Research Institute With Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria; General Hospital Linz, Linz, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Innsbruck Medical University, Innsbruck, Austria; Medical University Graz, Innsbruck, Austria; General Hospital Feldkirch, Feldkirch, Austria; County Hospital Steyr, Steyr, Austria; Division of Oncology, Medical University Graz, Graz, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - M Fridrik
- Salzburg Cancer Research Institute With Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria; General Hospital Linz, Linz, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Innsbruck Medical University, Innsbruck, Austria; Medical University Graz, Innsbruck, Austria; General Hospital Feldkirch, Feldkirch, Austria; County Hospital Steyr, Steyr, Austria; Division of Oncology, Medical University Graz, Graz, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - A Petzer
- Salzburg Cancer Research Institute With Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria; General Hospital Linz, Linz, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Innsbruck Medical University, Innsbruck, Austria; Medical University Graz, Innsbruck, Austria; General Hospital Feldkirch, Feldkirch, Austria; County Hospital Steyr, Steyr, Austria; Division of Oncology, Medical University Graz, Graz, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - M Hubalek
- Salzburg Cancer Research Institute With Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria; General Hospital Linz, Linz, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Innsbruck Medical University, Innsbruck, Austria; Medical University Graz, Innsbruck, Austria; General Hospital Feldkirch, Feldkirch, Austria; County Hospital Steyr, Steyr, Austria; Division of Oncology, Medical University Graz, Graz, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - E Petru
- Salzburg Cancer Research Institute With Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria; General Hospital Linz, Linz, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Innsbruck Medical University, Innsbruck, Austria; Medical University Graz, Innsbruck, Austria; General Hospital Feldkirch, Feldkirch, Austria; County Hospital Steyr, Steyr, Austria; Division of Oncology, Medical University Graz, Graz, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - T Jäger
- Salzburg Cancer Research Institute With Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria; General Hospital Linz, Linz, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Innsbruck Medical University, Innsbruck, Austria; Medical University Graz, Innsbruck, Austria; General Hospital Feldkirch, Feldkirch, Austria; County Hospital Steyr, Steyr, Austria; Division of Oncology, Medical University Graz, Graz, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - J Andel
- Salzburg Cancer Research Institute With Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria; General Hospital Linz, Linz, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Innsbruck Medical University, Innsbruck, Austria; Medical University Graz, Innsbruck, Austria; General Hospital Feldkirch, Feldkirch, Austria; County Hospital Steyr, Steyr, Austria; Division of Oncology, Medical University Graz, Graz, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - M Balic
- Salzburg Cancer Research Institute With Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria; General Hospital Linz, Linz, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Innsbruck Medical University, Innsbruck, Austria; Medical University Graz, Innsbruck, Austria; General Hospital Feldkirch, Feldkirch, Austria; County Hospital Steyr, Steyr, Austria; Division of Oncology, Medical University Graz, Graz, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - H Ulmer
- Salzburg Cancer Research Institute With Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria; General Hospital Linz, Linz, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Innsbruck Medical University, Innsbruck, Austria; Medical University Graz, Innsbruck, Austria; General Hospital Feldkirch, Feldkirch, Austria; County Hospital Steyr, Steyr, Austria; Division of Oncology, Medical University Graz, Graz, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - B Mlineritsch
- Salzburg Cancer Research Institute With Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria; General Hospital Linz, Linz, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Innsbruck Medical University, Innsbruck, Austria; Medical University Graz, Innsbruck, Austria; General Hospital Feldkirch, Feldkirch, Austria; County Hospital Steyr, Steyr, Austria; Division of Oncology, Medical University Graz, Graz, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - R Greil
- Salzburg Cancer Research Institute With Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria; General Hospital Linz, Linz, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Innsbruck Medical University, Innsbruck, Austria; Medical University Graz, Innsbruck, Austria; General Hospital Feldkirch, Feldkirch, Austria; County Hospital Steyr, Steyr, Austria; Division of Oncology, Medical University Graz, Graz, Austria; Medical University Innsbruck, Innsbruck, Austria
| |
Collapse
|
6
|
Kocher F, Dobner S, Föger B, Fiegl M, Fridrik M, Hubalek M, Lang A, Pall G, Petzer A, Wöll E, Hilbe W. Cardiovascular complications of cancer treatment: update CACOCA trial. Pneumologie 2015. [DOI: 10.1055/s-0035-1551918] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
7
|
Kocher F, Föger B, Fiegl M, Fridrik M, Gastl G, Lang A, Wanitschek M, Wöll E, Zabernigg A, Hilbe W. Update CACOCA Trial (cardiovascular complications of cancer treatment). Pneumologie 2014. [DOI: 10.1055/s-0034-1375924] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
8
|
Kocher F, Fridrik M, Gastl G, Petzer A, Samonigg H, Wöll E, Zabernigg A, Hilbe W. Long term cardiotoxicity in patients treated with chemotherapy and/or targeted drugs, a prospective non interventional trial. Pneumologie 2013. [DOI: 10.1055/s-0033-1345065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
9
|
Woell E, Greil R, Eisterer W, Fridrik M, Grünberger B, Zabernigg A, Mayrbäurl B, Russ G, Thaler J. Oxaliplatin, irinotecan, and cetuximab in advanced gastric cancer. First efficacy results of a multicenter phase II trial (AGMT Gastric-2) of the Arbeitsgemeinschaft Medikamentoese Tumortherapie (AGMT). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.4538] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4538 Background: Patients (pts.) suffering from advanced gastric cancer have still a poor prognosis and treatment options are limited. In our previous phase II trial (AGMT-Gastric-1) we could show that the combination of oxaliplatin and irinotecan was well tolerated and showed an objective response rate of 58% (Anticancer Res 28:2901–2906, 2008). This chemotherapy regimen was tested in combination with cetuximab in a multicenter phase II trial. Methods: Oxaliplatin 85 mg/m2 biweekly and irinotecan 125 mg/m2 biweekly were combined with cetuximab 400 mg/m2 loading dose and subsequently weekly 250 mg/m2. 51 patients with histological proven unresectable and/or metastatic gastric adenocarcinoma were treated in a first line setting. Median age: 62 years (range 19–79 years), PS 0: 25 patients, PS 1+2 26 patients, single metastatic site: 24 patients, multiple metastases: 27 patients. Results: Frequently reported adverse events (more than 20% of pts.) were predominantly grade 1 or 2 and included neutropenia (35% of pts.), thrombocytopenia (33%), anemia (73%), nausea (45%), diarrhea (57%), alopecia (22%), and fatigue (37%). Grade 3 and 4 toxicities included neutropenia in 9/1 pts., thrombocytopenia in 1/0 pts., anemia in 3/1 pts., nausea in 2/0 pts., and diarrhea in 7/2 pts. Sensory neuropathy occurred mostly as grade 1 and 2 in 37% of pts., in 7 pts. grade 3 neurotoxicity was observed. Acneiform skin rash grade 1 / 2 / 3 / 4 was reported in 31% / 20% / 6% / 2% of pts. respectively. 16 pts. went off-study due to neutropenia (n=5), nausea/vomiting (n=1), diarrhea (n=1), progressive disease (n=3), toxic colon (n=2), and allergic reaction to cetuximab at first (n=2), second (n=1) or third infusion (n=1). 35 patients are assessable for response with 1 pt. (3%) showing a CR, 21 pts. (60%) a PR, 7 pts. (20%) a SD and PD in 6 pts. (17%). A disease control rate was achieved in 83%. Median time to progression was 24.8 weeks (n=29), median overall survival 38.1 weeks (n=32). Conclusions: The combination of oxaliplatin and irinotecan with cetuximab is feasible, safe and active in advanced gastric cancer. [Table: see text]
Collapse
Affiliation(s)
- E. Woell
- Saint Vincent Hospital Zams, Zams, Austria; III. Medizinische Universitätsklinik, Salzburg, Austria; Universitätsklinik für Innere Medizin I, Innsbruck, Austria; AKH Linz, Linz, Austria; Krankenanstalt Rudolfstiftung, Vienna, Austria; BKH Kufstein, Kufstein, Austria; Klinikum Wels, Wels, Austria
| | - R. Greil
- Saint Vincent Hospital Zams, Zams, Austria; III. Medizinische Universitätsklinik, Salzburg, Austria; Universitätsklinik für Innere Medizin I, Innsbruck, Austria; AKH Linz, Linz, Austria; Krankenanstalt Rudolfstiftung, Vienna, Austria; BKH Kufstein, Kufstein, Austria; Klinikum Wels, Wels, Austria
| | - W. Eisterer
- Saint Vincent Hospital Zams, Zams, Austria; III. Medizinische Universitätsklinik, Salzburg, Austria; Universitätsklinik für Innere Medizin I, Innsbruck, Austria; AKH Linz, Linz, Austria; Krankenanstalt Rudolfstiftung, Vienna, Austria; BKH Kufstein, Kufstein, Austria; Klinikum Wels, Wels, Austria
| | - M. Fridrik
- Saint Vincent Hospital Zams, Zams, Austria; III. Medizinische Universitätsklinik, Salzburg, Austria; Universitätsklinik für Innere Medizin I, Innsbruck, Austria; AKH Linz, Linz, Austria; Krankenanstalt Rudolfstiftung, Vienna, Austria; BKH Kufstein, Kufstein, Austria; Klinikum Wels, Wels, Austria
| | - B. Grünberger
- Saint Vincent Hospital Zams, Zams, Austria; III. Medizinische Universitätsklinik, Salzburg, Austria; Universitätsklinik für Innere Medizin I, Innsbruck, Austria; AKH Linz, Linz, Austria; Krankenanstalt Rudolfstiftung, Vienna, Austria; BKH Kufstein, Kufstein, Austria; Klinikum Wels, Wels, Austria
| | - A. Zabernigg
- Saint Vincent Hospital Zams, Zams, Austria; III. Medizinische Universitätsklinik, Salzburg, Austria; Universitätsklinik für Innere Medizin I, Innsbruck, Austria; AKH Linz, Linz, Austria; Krankenanstalt Rudolfstiftung, Vienna, Austria; BKH Kufstein, Kufstein, Austria; Klinikum Wels, Wels, Austria
| | - B. Mayrbäurl
- Saint Vincent Hospital Zams, Zams, Austria; III. Medizinische Universitätsklinik, Salzburg, Austria; Universitätsklinik für Innere Medizin I, Innsbruck, Austria; AKH Linz, Linz, Austria; Krankenanstalt Rudolfstiftung, Vienna, Austria; BKH Kufstein, Kufstein, Austria; Klinikum Wels, Wels, Austria
| | - G. Russ
- Saint Vincent Hospital Zams, Zams, Austria; III. Medizinische Universitätsklinik, Salzburg, Austria; Universitätsklinik für Innere Medizin I, Innsbruck, Austria; AKH Linz, Linz, Austria; Krankenanstalt Rudolfstiftung, Vienna, Austria; BKH Kufstein, Kufstein, Austria; Klinikum Wels, Wels, Austria
| | - J. Thaler
- Saint Vincent Hospital Zams, Zams, Austria; III. Medizinische Universitätsklinik, Salzburg, Austria; Universitätsklinik für Innere Medizin I, Innsbruck, Austria; AKH Linz, Linz, Austria; Krankenanstalt Rudolfstiftung, Vienna, Austria; BKH Kufstein, Kufstein, Austria; Klinikum Wels, Wels, Austria
| |
Collapse
|
10
|
Woell E, Greil R, Eisterer W, Fridrik M, Grünberger B, Gattringer K, Mayrbäurl B, Russ G, Thaler J. Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer: First results of a multicenter phase II trial (AGMT Gastric- 2. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.15587] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
11
|
Ludwig H, Drach J, Tóthová E, Gisslinger H, Jaksic B, Linkesch W, Hajek R, Greil R, Fridrik M, Labar B, Zojer N. Thalidomide-dexamethasone versus melphalan-prednisolone as first line treatment in elderly patients with multiple myeloma: An interim analysis. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.6537] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- H. Ludwig
- Wilhelminenhospital, Vienna, Austria; Univ Hosp, Vienna, Austria; Univ Hosp PJS, Kosice, Slovakia; Kl. Krank. Merkur, Zagreb, Croatia; Univ Hosp, Graz, Austria; Faculty Hosp, Brno, Czech Republic; LKH, Salzburg, Austria; Allgemeines Krankenhaus, Linz, Austria; Clin Hosp Rebro, Zagreb, Croatia
| | - J. Drach
- Wilhelminenhospital, Vienna, Austria; Univ Hosp, Vienna, Austria; Univ Hosp PJS, Kosice, Slovakia; Kl. Krank. Merkur, Zagreb, Croatia; Univ Hosp, Graz, Austria; Faculty Hosp, Brno, Czech Republic; LKH, Salzburg, Austria; Allgemeines Krankenhaus, Linz, Austria; Clin Hosp Rebro, Zagreb, Croatia
| | - E. Tóthová
- Wilhelminenhospital, Vienna, Austria; Univ Hosp, Vienna, Austria; Univ Hosp PJS, Kosice, Slovakia; Kl. Krank. Merkur, Zagreb, Croatia; Univ Hosp, Graz, Austria; Faculty Hosp, Brno, Czech Republic; LKH, Salzburg, Austria; Allgemeines Krankenhaus, Linz, Austria; Clin Hosp Rebro, Zagreb, Croatia
| | - H. Gisslinger
- Wilhelminenhospital, Vienna, Austria; Univ Hosp, Vienna, Austria; Univ Hosp PJS, Kosice, Slovakia; Kl. Krank. Merkur, Zagreb, Croatia; Univ Hosp, Graz, Austria; Faculty Hosp, Brno, Czech Republic; LKH, Salzburg, Austria; Allgemeines Krankenhaus, Linz, Austria; Clin Hosp Rebro, Zagreb, Croatia
| | - B. Jaksic
- Wilhelminenhospital, Vienna, Austria; Univ Hosp, Vienna, Austria; Univ Hosp PJS, Kosice, Slovakia; Kl. Krank. Merkur, Zagreb, Croatia; Univ Hosp, Graz, Austria; Faculty Hosp, Brno, Czech Republic; LKH, Salzburg, Austria; Allgemeines Krankenhaus, Linz, Austria; Clin Hosp Rebro, Zagreb, Croatia
| | - W. Linkesch
- Wilhelminenhospital, Vienna, Austria; Univ Hosp, Vienna, Austria; Univ Hosp PJS, Kosice, Slovakia; Kl. Krank. Merkur, Zagreb, Croatia; Univ Hosp, Graz, Austria; Faculty Hosp, Brno, Czech Republic; LKH, Salzburg, Austria; Allgemeines Krankenhaus, Linz, Austria; Clin Hosp Rebro, Zagreb, Croatia
| | - R. Hajek
- Wilhelminenhospital, Vienna, Austria; Univ Hosp, Vienna, Austria; Univ Hosp PJS, Kosice, Slovakia; Kl. Krank. Merkur, Zagreb, Croatia; Univ Hosp, Graz, Austria; Faculty Hosp, Brno, Czech Republic; LKH, Salzburg, Austria; Allgemeines Krankenhaus, Linz, Austria; Clin Hosp Rebro, Zagreb, Croatia
| | - R. Greil
- Wilhelminenhospital, Vienna, Austria; Univ Hosp, Vienna, Austria; Univ Hosp PJS, Kosice, Slovakia; Kl. Krank. Merkur, Zagreb, Croatia; Univ Hosp, Graz, Austria; Faculty Hosp, Brno, Czech Republic; LKH, Salzburg, Austria; Allgemeines Krankenhaus, Linz, Austria; Clin Hosp Rebro, Zagreb, Croatia
| | - M. Fridrik
- Wilhelminenhospital, Vienna, Austria; Univ Hosp, Vienna, Austria; Univ Hosp PJS, Kosice, Slovakia; Kl. Krank. Merkur, Zagreb, Croatia; Univ Hosp, Graz, Austria; Faculty Hosp, Brno, Czech Republic; LKH, Salzburg, Austria; Allgemeines Krankenhaus, Linz, Austria; Clin Hosp Rebro, Zagreb, Croatia
| | - B. Labar
- Wilhelminenhospital, Vienna, Austria; Univ Hosp, Vienna, Austria; Univ Hosp PJS, Kosice, Slovakia; Kl. Krank. Merkur, Zagreb, Croatia; Univ Hosp, Graz, Austria; Faculty Hosp, Brno, Czech Republic; LKH, Salzburg, Austria; Allgemeines Krankenhaus, Linz, Austria; Clin Hosp Rebro, Zagreb, Croatia
| | - N. Zojer
- Wilhelminenhospital, Vienna, Austria; Univ Hosp, Vienna, Austria; Univ Hosp PJS, Kosice, Slovakia; Kl. Krank. Merkur, Zagreb, Croatia; Univ Hosp, Graz, Austria; Faculty Hosp, Brno, Czech Republic; LKH, Salzburg, Austria; Allgemeines Krankenhaus, Linz, Austria; Clin Hosp Rebro, Zagreb, Croatia
| |
Collapse
|
12
|
Schrenk P, Moser F, Wölfl S, Bogner S, Fridrik M, Gitter T, Hochreiner G, Wayand W. Use of reduction mammoplasty techniques in breast cancer conservation therapy. EJC Suppl 2004. [DOI: 10.1016/s1359-6349(04)90977-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
13
|
Kühr T, Burgstaller S, Apfelbeck U, Linkesch W, Seewann H, Fridrik M, Michlmayr G, Krieger O, Lutz D, Lin W, Pont J, Köck L, Abbrederis K, Baldinger C, Buder R, Geissler D, Hausmaninger H, Lang A, Zabernigg A, Duba C, Hilbe W, Eisterer W, Fiegl M, Greil R, Gastl G, Thaler J. A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML). Leuk Res 2003; 27:405-11. [PMID: 12620292 DOI: 10.1016/s0145-2126(02)00223-0] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
This multicenter randomized phase III study was designed to compare the efficacy and toxicity of IFN alpha-2c (3.5 MU/d) in combination with either araC (10 mg/m(2) d1-10) or hydroxyurea (HU: 25 mg/kg per day) in newly diagnosed CML patients. A total of 114 patients were randomized. Following a median observation period of 36 (range 1-73) months the major cytogenetic response rates were 25 and 27% and the 4-year survival probabilities 62.5 and 63% for the araC and HU group, respectively. While the overall toxicity profile was comparable between both groups, patients in the HU arm exhibited a slightly higher degree of WHO grades 3 and 4 non-hematological toxicities.
Collapse
Affiliation(s)
- T Kühr
- Department of Internal Medicine, General Hospital, Grieskirchnerstr. 42, A-4600 Wels, Austria.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Ploner F, Jakesz R, Hausmaninger H, Kolb R, Stierer M, Fridrik M, Steindorfer P, Gnant M, Haider K, Mlineritsch B, Tschurtschenthaler G, Steger G, Seifert M, Kubista E, Samonigg H. Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients. Oncol Res Treat 2003; 26:115-9. [PMID: 12771518 DOI: 10.1159/000069831] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
AIM A randomised, controlled clinical trial was initiated in 1984 to test whether 1 cycle of anthracycline-containing adjuvant chemotherapy improves the outcome of breast cancer patients presenting with stage II disease and negative oestrogen and progesterone receptors (ER, PgR), as compared with 6 cycles of dose-reduced CMF. PATIENTS AND METHODS Within 7 years 263 women with stage II breast cancer were randomised either to receive 1 cycle of doxorubicin, vinblastine, cyclophosphamide, methotrexate and 5- fluorouracil (AV-CMF) or to receive 6 cycles of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Patients were stratified for tumour stage, nodal stage, menopausal status, type of surgery and participating centre. RESULTS After a median follow-up of 100 months, neither disease-free (DFS) nor overall survival (OS) differed significantly between the two groups. CONCLUSIONS Compared to 6 cycles of a non-standard low-dose CMF regimen 1 cycle of anthracycline- containing adjuvant chemotherapy failed to improve the outcome in women with stage II receptor-negative breast cancer in terms of DFS and OS.
Collapse
MESH Headings
- Antineoplastic Combined Chemotherapy Protocols/adverse effects
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Breast Neoplasms/drug therapy
- Breast Neoplasms/mortality
- Breast Neoplasms/pathology
- Carcinoma, Ductal, Breast/drug therapy
- Carcinoma, Ductal, Breast/mortality
- Carcinoma, Ductal, Breast/pathology
- Carcinoma, Lobular/drug therapy
- Carcinoma, Lobular/mortality
- Carcinoma, Lobular/pathology
- Chemotherapy, Adjuvant
- Cisplatin/adverse effects
- Cisplatin/therapeutic use
- Combined Modality Therapy
- Cyclophosphamide/adverse effects
- Cyclophosphamide/therapeutic use
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Doxorubicin/adverse effects
- Doxorubicin/therapeutic use
- Drug Administration Schedule
- Female
- Fluorouracil/adverse effects
- Fluorouracil/therapeutic use
- Humans
- Lymphatic Metastasis
- Methotrexate/adverse effects
- Methotrexate/therapeutic use
- Middle Aged
- Neoplasm Staging
- Receptors, Estrogen/analysis
- Receptors, Progesterone/analysis
- Survival Rate
- Vincristine/adverse effects
- Vincristine/therapeutic use
Collapse
Affiliation(s)
- F Ploner
- Klinische Abteilung für Onkologie, Medizinische Universitätsklinik, Karl-Franzens-Universität Graz.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Hilbe W, Kühr T, Apfelbeck U, Fridrik M, Seewann H, Stöger M, Linkesch W, Pont J, Baldinger C, Hartner E, Bernhart M, Geissler D, Krieger O, Lang A, Lin W, Ludwig H, Duba C, Greil R, Gast G, Thaler J. Dose escalation of ara-c may improve response rates in a subgroup of chronic myeloid leukemia patients with poor response to interferon-alpha and low-dose ara-C. Leuk Lymphoma 2001; 42:1283-8. [PMID: 11911409 DOI: 10.3109/10428190109097753] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
The present analysis was performed to evaluate the impact of cytosine arabinoside (ara-C) dose escalation on hematological and cytogenetic responses in patients with chronic myelogenous leukemia (CML) who failed to respond to low-dose ara-C (LD ara-C) at a dose of 10 mg/m2/d over 10 days per month and interferon-alpha (IFNalpha, 3.5 MU/d). Following the same administration schedule, dose escalation of ara-C to 15 and 20 mg/m2/d 1-10 was performed in 36 of 119 patients (30%) due to inadequate hematological response and/or disease progression. As a result, improvement of hematological and cytogenetic responses was achieved in 22 (61%) and nine (25%) patients, respectively. Escalated ara-C dose levels were usually well tolerated, although some patients experienced deterioration of preexisting side effects. Our results support the critical role of ara-C dose towards a better disease control in CML.
Collapse
Affiliation(s)
- W Hilbe
- Department of Internal Medicine, University Hospital, Innsbruck, Austria
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Hilbe W, Kühr T, Apfelbeck U, Fridrik M, Seewann H, Stöger M, Linkesch W, Pont J, Baldinger C, Hartner E, Bernhart M, Geissler D, Krieger O, Lang A, Lin W, Ludwig H, Duba C, Greil R, Gastl G, Thaler J. Dose Escalation of Ara-C May Improve Response Rates in a Subgroup of Chronic Myeloid Leukemia Patients with Poor Response to Interferon-α and Low-dose Ara-C. Leuk Lymphoma 2001. [DOI: 10.1080/10428190127503] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
17
|
Pichler R, Maschek W, Hatzl-Griesenhofer M, Huber H, Wimmer G, Wahl G, Fridrik M. [Clinical value of FDG PET using coincident gamma cameras in staging and restaging of malignant lymphoma--compared with convenitonal diagnostic methods]. Nuklearmedizin 2000; 39:166-73. [PMID: 11057408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2023]
Abstract
UNLABELLED AIM of the present retrospective study was to validate the clinical value of F-18-FDG PET imaging in lymphoma patients with a dual head camera modified for coincidence detection. Staging before and after oncological treatment was compared with a conservative diagnostic approach. METHODS 48 patients (28 non-Hodgkin lymphoma, 20 Hodgkin's disease) received FDG-Hybrid-PET scans. Pretherapeutic staging was realized in 28 patients, 9 of them had control studies after they had completed therapy. Totally 29 persons were examined for post-therapeutic restaging. Computed tomography imaging and lymph node sonography was performed in all cases. Results were validated by clinical follow-up, in three cases a recidive was proven by biopsy. RESULTS CT and ultrasound detected 77 lesions in 28 patients compared with 100 visualized by PET, but this difference in pretherapeutic staging did not reach significance at p > 0.05 by Fisher's t-test. Hybrid-PET obtained a sensitivity of 93%, a specificity of 79%, a positive of 82% and a negative predictive value of 92% for detection of residual disease. The values for CT + US were 87%, 64%, 72% and 88% respectively. CONCLUSION FDG Hybrid-PET is as or even more accurate than standard morphologic diagnostic methods for prestaging in malignant lymphoma. Additionally, there is a substantial benefit for therapy monitoring of residual disease using coincidence detection PET with a 3/4-inch crystal gamma camera.
Collapse
Affiliation(s)
- R Pichler
- Institut für Nuklearmedizin, Allgemeinen Krankenhauses Linz, Osterreich
| | | | | | | | | | | | | |
Collapse
|
18
|
Jakesz R, Hausmaninger H, Haider K, Kubista E, Samonigg H, Gnant M, Manfreda D, Tschurtschenthaler G, Kolb R, Stierer M, Fridrik M, Mlineritsch B, Steindorfer P, Mittlböck M, Steger G. Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer. J Clin Oncol 1999; 17:1701-9. [PMID: 10561206 DOI: 10.1200/jco.1999.17.6.1701] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE To evaluate the outcome in patients with stage II hormone receptor-positive breast cancer treated or not treated with low-dose, short-term chemotherapy in addition to tamoxifen in terms of disease-free and overall survival. PATIENTS AND METHODS A total of 613 patients were randomized to receive either low-dose chemotherapy (doxorubicin 20 mg/m(2) and vincristine 1 mg/m(2) on day 1; cyclophosphamide 300 mg/m(2); methotrexate 25 mg/m(2); and fluorouracil 600 mg/m(2) on days 29 and 36 intravenously) or no chemotherapy in addition to 20 mg of tamoxifen orally for 2 years. A third group without any treatment (postmenopausal patients only) was terminated after the accrual of 79 patients due to ethical reasons. RESULTS After a median follow-up period of 7.5 years, the addition of chemotherapy did not improve the outcome in patients as compared with those treated with tamoxifen alone, neither with respect to disease-free nor overall survival. Multivariate analysis of prognostic factors for disease-free survival revealed menopausal status, in addition to nodal status, progesterone receptor, and histologic grade as significant. Both untreated postmenopausal and tamoxifen-treated premenopausal patients showed identical prognoses significantly inferior to the tamoxifen-treated postmenopausal cohort. Prognostic factors for overall survival in the multivariate analysis showed nodal and tumor stage, tumor grade, and hormone receptor level as significant. CONCLUSION Low-dose chemotherapy in addition to tamoxifen does not improve the prognosis of stage II breast cancer patients with hormone-responsive tumors. Tamoxifen-treated postmenopausal patients show a significantly better prognosis than premenopausal patients, favoring the hypothesis of a more pronounced effect of tamoxifen in the older age groups.
Collapse
Affiliation(s)
- R Jakesz
- Department of Surgery, Internal Medicine, and Gynecology and Obstetrics, University of Vienna, Austria.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Jakesz R, Hausmaninger H, Samonigg H, Kubista E, Haider K, Mlineritsch B, Schmid M, Tausch C, Reiner G, Renner K, Stierer M, Jatzko G, Hofbauer F, Fridrik M, Schennach W, Sevelda P, Dadak C, Haid A, Scholz R, Lenzhofer P, Steindorfer P, Berger A, Mischinger HJ. [Therapy studies of the Austrian Breast Cancer Group (ABC)]. Zentralbl Chir 1999; 123 Suppl 5:28-32. [PMID: 10063568] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/11/2023]
Abstract
The Austrian Breast Cancer Group (ABC) consisting of more than 60 participating centers in Austria has randomized more than 5800 patients in 11 randomized trials since 1984. At present, roughly 30% of all patients with the diagnosis primary breast cancer are accrued in protocols throughout the country. Due to specific activities, the breast conservation rate raised from an initial 20% to more than 60% in the last years. Multicenter trials are not only the basis for progress in medicine but also tools for quality control and quality improvement.
Collapse
Affiliation(s)
- R Jakesz
- Klinische Abteilung für Allgemeinchirurgie, Universitätsklinik für Chirurgie Wien
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Hausmaninger H, Moser R, Samonigg H, Mlineritsch B, Schmidt H, Pecherstorfer M, Fridrik M, Kopf C, Nitsche D, Kaider A, Ludwig H. Biochemical modulation of 5-fluorouracil by leucovorin with or without interferon-alpha-2c in patients with advanced colorectal cancer: final results of a randomised phase III study. Eur J Cancer 1999; 35:380-5. [PMID: 10448286 DOI: 10.1016/s0959-8049(98)00397-9] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
5-Fluorouracil (5-FU) remains the mainstay of treatment for advanced colorectal carcinoma, although response rates are generally less than 20%. Improved therapeutic efficacy has been reported using biochemical modulation of 5-FU by leucovorin (LV) or interferon alpha (IFN), the combination of 5-FU/LV frequently considered as standard therapy in metastatic colorectal cancer. In an attempt to enhance the cytotoxicity of 5-FU, a prospective randomised trial was initiated to compare 5-FU/LV with 5-FU/LV plus IFN. Patients were randomised to receive either LV, 100 mg/m2 intravenously (i.v.), followed by 5-FU, 500 mg/m2 as a 1-h i.v. infusion, daily for 4 days, followed by weekly infusions until week 8, or the same regimen of 5-FU/LV plus IFN-alpha-2c, 30 micrograms subcutaneously (s.c.), three times weekly. Cycles were repeated after a 2-week rest period. Among 269 enrolled patients, 219 were available for response and 243 for toxicity. An objective tumour response was observed in 38 of 107 (36%) and 28 of 112 (25%) patients in the treatment arms with and without IFN, respectively (difference not significant). There was no significant difference between the two groups in response duration (median 8.4 versus 12.1 months), time to treatment failure (median 6.5 versus 4.9 months), or overall survival (median 10.0 versus 12.6 months). However, patients in the IFN arm experienced significantly more haematological and gastrointestinal toxicity and more frequent alopecia. In conclusion, the addition of IFN to 5-FU/LV in the schedules and doses used in the study did not provide any clinical benefit over 5-FU/LV alone and cannot be recommended for routine use in the treatment of advanced colorectal cancer.
Collapse
|
21
|
Kucera E, Speiser P, Gnant M, Szabo L, Samonigg H, Hausmaninger H, Mittlböck M, Fridrik M, Seifert M, Kubista E, Reiner A, Zeillinger R, Jakesz R. Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients. Austrian Breast Cancer Study Group. Eur J Cancer 1999; 35:398-405. [PMID: 10448289 DOI: 10.1016/s0959-8049(98)00400-6] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
The aim of our study was to evaluate if p53 mutations, especially those in the L2/L3 domains of the p53 gene, add prognostic information for node-positive and steroid receptor positive breast cancer patients. Two hundred and five tumour samples from a randomised clinical trial of 596 lymph node- and steroid receptor positive breast cancer patients were included. All patients had been randomly allocated to receive 20 mg of adjuvant tamoxifen (TAM) daily for 2 years or TAM plus one cycle of low-dose, short-term chemotherapy. For detection of p53 mutations we used in vitro amplification by polymerase chain reaction and consecutively performed temperature gradient gel electrophoresis (PCR-TGGE) and direct sequencing. We found p53 mutations in 42/205 (20%) cases: 16/42 (38%) p53 mutations occurred within the L2/L3 domains of the p53 gene, and 26/42 (62%) outside the L2/L3 domains. p53 mutation served as a statistically significant parameter in predicting disease-free survival in univariate (P = 0.02) and multivariate (P = 0.009) analysis. For overall survival, no significant differences were observed. Patients with tumours that had p53 mutations within the L2/L3 domains of the gene showed no significant difference to those with mutations outside the L2/L3 domains for disease-free survival. For overall survival, mutations in the L2/L3 domains showed a marginally significant difference (P = 0.05) in multivariate analysis, but not in univariate analysis (P = 0.13). We conclude that mutation in the L2/L3 domains of the p53 gene is not an independent prognostic indicator of disease outcome for patients suffering from breast cancer with lymph node metastases and positive steroid receptors.
Collapse
Affiliation(s)
- E Kucera
- Department of Gynaecology and Obstetrics, University of Vienna Medical School, Austria.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Duba HC, Peter S, Hilbe W, Fluckinger T, Fridrik M, Erdel M, Thaler J, Utermann G. Monitoring of remission status by fluorescence in situ hybridisation in chronic myeloid leukaemia patients treated with interferon-alpha. Int J Oncol 1999; 14:145-50. [PMID: 9863021 DOI: 10.3892/ijo.14.1.145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
Interferon-alpha (IFN-alpha) can be considered as treatment of choice for patients with chronic myeloid leukaemia (CML) in chronic phase. With this treatment major cytogenetic responses can be achieved in 30% to 50% of patients. Regular monitoring of cytogenetic response is essential for the therapeutic management of these patients. As conventional cytogenetics is not always successful, especially under IFN-alpha treatment, molecular cytogenetic methods have been established for the examination of interphase nuclei for the presence of the BCR-ABL fusion gene, the molecular counterpart of the Philadelphia chromosome. To demonstrate the value of these new methods we have analysed interphase nuclei from sequentially cultured bone marrow cells from 14 CML patients who were treated with IFN-alpha and whose bone marrow was investigated regularly during therapy. Dual-colour FISH with a breakpoint spanning BCR-YAC and a flanking cosmid from the ABL region was applied. When compared with conventional cytogenetics the results achieved by FISH were favourable. The most evident advantage of FISH analysis is that in case of failure of conventional cytogenetics a reliable determination of the remission status can be done. Together with other recent studies our results illustrate the advantages and limitations of the interphase FISH method for monitoring CML patients.
Collapse
Affiliation(s)
- H C Duba
- Institut für Medizinische Biologie und Humangenetik der Universität Innsbruck, A-6020 Innsbruck, Austria
| | | | | | | | | | | | | | | |
Collapse
|
23
|
Hilbe W, Apfelbeck U, Fridrik M, Bernhart M, Niessner H, Abbrederis K, Michlmayr G, Pont J, Linkesch W, Hausmaninger H, Arneitz K, Baldinger C, Duba C, Eisterer W, Greil R, Konwalinka G, Niederwieser D, Gastl G, Thaler J. Interferon-alpha for the treatment of elderly patients with chronic myeloid leukaemia. Leuk Res 1998; 22:881-6. [PMID: 9766747 DOI: 10.1016/s0145-2126(98)00064-2] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
The present retrospective analysis is based on data of 213 patients with chronic myeloid leukaemia (CML). They were treated with interferon (IFN)alpha-2C (Berofor) at daily doses of 3.5 MU subcutaneously (s.c.), alone or in combination with low-dose ara-C or hydroxyurea, according to four consecutive studies of the Austrian CML Study Group. Comparisons were made between 41 patients aged > or = 60 years and 172 younger patients. The elderly patients (median: 64 years; range: 60-73) showed similar pretreatment characteristics compared with the younger group, but included a higher percentage of Sokal Stage three (51 vs 20%). Median observation periods were similar (38 vs 39 months), whereas the duration of IFNalpha treatment was shorter in the elderly group (median 57 vs 42 weeks). The rate of overall haematological responses (73 vs 78%) and complete haematological response (44 vs 54%), was similar in both cohorts. Differences seen in partial (5 vs 12%) and complete cytogenetic response (10 vs 13%), were not statistically significant, but a tendency in favour of the younger cohort had to be noted. Summing up, in elderly patients acceptable rates of haematological and cytogentic response can be expected after treatment with IFNalpha alone or in combination with LD ara-C or HU.
Collapse
Affiliation(s)
- W Hilbe
- Department of Internal Medicine, University Hospital, Innsbruck, Austria
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Tschurtschenthaler G, Oppitz P, Hammer J, Flink P, Fridrik M, Michlmayr G. P3 The effect of medical information on womens opinion about breast cancer. Eur J Cancer 1998. [DOI: 10.1016/s0959-8049(97)89221-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
25
|
Jakesz R, Samonigg H, Gnant M, Kubista E, Steindorfer P, Hausmaninger H, Sevelda P, Tschurtschenthaler B, Fridrik M, Stierer M, Kolb R, Steger G. Very low-dose adjuvant chemotherapy in steroid receptor negative stage I breast cancer patients. Austrian Breast Cancer Study Group. Eur J Cancer 1998; 34:66-70. [PMID: 9624239 DOI: 10.1016/s0959-8049(97)10010-7] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
A randomised clinical trial was performed to test whether or not low-dose chemotherapy lasting only 35 days improves the outcome of breast cancer patients with stage I disease and negative oestrogen and progesterone receptors (ER-, PgR-). Between 1984 and 1990, 277 stage I breast cancer patients with tumours negative for both oestrogen and progesterone receptors were randomised to receive either low-dose short-term chemotherapy or no chemotherapy. Chemotherapy consisted of one cycle of doxorubicin, vincristin (AV) and one cycle of cyclophosphamide, methotrexate, fluorouracil (CMF). Patients were stratified for tumour stage, type of surgery, menopausal status and participating centre. Results were analysed both by univariate and multivariate statistical. After a median length of follow-up of 84 months, disease-free (DFS) and overall survival (OS) did not differ significantly between patients having received adjuvant chemotherapy and the control group. Uni- and multivariate analysis did not show any significant prognostic or therapy related factor. A low-dose short-term adjuvant chemotherapy is insufficient to improve the prognosis of patients with breast cancer stage I with ER-, PgR-tumours.
Collapse
|
26
|
|
27
|
Jakesz R, Gnant M, Schmid M, Samonigg H, Steindorfer P, Hausmaninger H, Sevelda P, Depisch D, Tausch C, Reiner G, Renner K, Stierer M, Pilz E, Jatzko G, Hofbauer F, Fridrik M, Schennach W, Dadak C, Haid A, Kubista E, Scholz R, Sagaster P, Winter R, Lenzhofer R. Abgeschlossene und derzeit laufende adjuvante Therapieprotokolle bei Patientinnen mit operablem Mammakarzinom (II). Eur Surg 1997. [DOI: 10.1007/bf02619741] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
28
|
Thaler J, Hilbe W, Apfelbeck U, Linkesch W, Sill H, Seewann H, Pont J, Bernhart M, Stöger M, Niessner H, Abbrederis K, Geissler D, Hausmaninger H, Lin W, Ludwig H, Lang A, Duba C, Fluckinger T, Greil R, Grünewald K, Konwalinka G, Niederwieser D, Fridrik M. Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: results of the Austrian multi-center phase II study. Leuk Res 1997; 21:75-80. [PMID: 9029189 DOI: 10.1016/s0145-2126(96)00084-7] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Small pilot studies of patients with CML have reported on encouraging response rates after treatment with interferon-alpha (IFNalpha) in combination with low-dose cytosine arabinoside (LD ara-C). We therefore initiated a multi-center phase II trial in order to investigate the efficacy and tolerability of this combination in newly diagnosed patients with Ph-positive chronic myelogenous leukemia (CML). Eighty-four patients were treated with IFN-alpha-2c at daily subcutaneous doses of 3.5 MU and LD ara-C added subcutaneously for 10 days every month at a dose of 10 mg/m2, following an initial reduction of WBC to less than 20 x 10(9)/l with hydroxyurea (HU). Within a median observation period of 28 (5-59) months the patients received a median of 7 (1-35) IFNalpha and LD ara-C cycles. Treatment was stopped due to side effects in 16 cases (19%) and to primary or secondary treatment failure in 38 cases (45%). In 45 patients (54%) complete hematological response (CHR) was achieved; in 39 patients (46%) cytogenetic responses including 15 (18%) complete cytogenetic responses (CHR) were observed. Median duration of cytogenetic responses was 15 months. Relapses were seen in 8/15 patients (53%) with complete cytogenetic remission (CCR), in 3/6 patients (50%) with partial cytogenetic response and in 9/18 patients (50%) with minor cytogenetic response. In conclusion, the combination of IFNalpha and LD ara-C resulted in encouraging rates of hematological and cytogenetic responses in patients with CML with low to moderate toxicity.
Collapse
Affiliation(s)
- J Thaler
- Department of Internal Medicine, University Hospital, Innsbruck, Austria
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Hausmaninger H, Lehnert M, Steger G, Sevelda P, Tschurtschenthaler G, Hehenwarter W, Fridrik M, Samonigg H, Schiller L, Manfreda D. Randomised phase II study of epirubicin-vindesine versus mitoxantrone-vindesine in metastatic breast cancer. Eur J Cancer 1995; 31A:2169-73. [PMID: 8652237 DOI: 10.1016/0959-8049(95)00489-0] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
The purpose of this study was to compare the activity and toxicity of epirubicin-vindesine (EV) with mitoxantrone-vindesine (MV) in patients with metastatic breast cancer. A total of 295 patients was randomly allocated to treatment with vindesine 3 mg/m2 combined with either epirubicin 40 mg/m2 or mitoxantrone 10 mg/m2. All drugs were given by intravenous push, treatment cycles were repeated at 3-4 week intervals. 255 patients were available for response, and 283 for toxicity. EV and MV yielded similar objective response rates (34 and 26%, respectively), response durations, times to progression and survival. Median time to remission was 1.8 and 3.1 months (P = 0.006) with EV and MV, respectively. In patients with visceral metastases, response rate was higher with EV than MV (40 versus 23%; P = 0.03). Patients receiving MV had less nausea/vomiting (P = 0.007) and alopecia (P = < 0.001) of WHO grade > or = 2. Bone marrow, cardiac and other toxicities were mild with both treatments. The observed differences in activity and toxicity between the two regimens appear to have clinical relevance. EV proved to be more active in visceral disease and to be able to induce remissions more rapidly. Accordingly, patients with visceral metastases or severe tumour-related symptoms may benefit from epirubicin-based treatment. Subjective toxicities, i.e. nausea/vomiting and alopecia, were less frequent and severe with MV. Thus, MV may prove useful in patients with more indolent disease and appears to warrant phase III evaluation in such patients.
Collapse
|
30
|
Hubmann R, Kaiser W, Radaszkiewicz T, Fridrik M, Zazgornik I. Malabsorption associated with a high-grade-malignant non-Hodgkin's lymphoma, alpha-heavy-chain disease and immunoproliferative small intestinal disease. Z Gastroenterol 1995; 33:209-13. [PMID: 7793120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
We report on a 28 year old Turkish woman, who was admitted to our hospital with the symptoms of malabsorption and protein-loosing enteropathy. Histologically, on duodenal biopsy, a lymphoplasmacellular infiltration of the submucosa with partial to subtotal atrophy of the villi was found. An immunoproliferative small intestinal disease (IPSID) was diagnosed. A short remission whilst on a glutenfree diet and tetracycline therapy, was followed by a laparatomy because of ileus in the small intestine. A high-grade-malignant Non-Hodgkin's Lymphome of B-cell type with intracellular production of alpha-Heavy-Chains (AHCD) was diagnosed histologically. Following chemotherapy with CEOP-IMVP-Dexa (Cyclophosphamide, Epidoxorubicin, Vincristine, Prednisolone, Ifosfamide, VP-16, Dexamethason, Methotrexat) the patient is still in complete remission three years after starting the therapy. We discuss here a case of AHCD in IPSID, the differential diagnosis of protein losing enteropathy and malabsorption, and we also present conservative (diet, medical treatment) and operative therapies.
Collapse
Affiliation(s)
- R Hubmann
- II. Department of Internal Medicine, General Hospital Linz, Austria
| | | | | | | | | |
Collapse
|
31
|
Moser R, Hausmaninger H, Ludwig H, Fridrik M, Schmidt H, Mlineritsch B, Pecherstorfer M, Michlmayr G, Kopf C, Samonigg H. 5-Fluorouracil and Folinic Acid with or without Alpha-2c Interferon in the Treatment of Metastatic Colorectal Cancer: Preliminary Results of a Multicenter Prospective Randomized Phase-Ill Trial. Oncol Res Treat 1995. [DOI: 10.1159/000218573] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
32
|
Hausmaninger H, Lehnert M, Steger G, Sevelda P, Michlmayr G, Hehenwarter W, Fridrik M, Samonigg H, Schiller L, Manfreda D. Vindesine-epirubicin versus vindesine-mitoxantrone in metastatic breast cancer. Onkologie 1989; 12:225-9. [PMID: 2685688 DOI: 10.1159/000216651] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
UNLABELLED The present study was designed to assess the toxicity and efficacy of two chemotherapy protocols in patients with metastatic breast cancer. Starting in December 1985, 230 patients were randomized to receive vindesine (V) (3 mg/m2 i.v.) and mitoxantrone (M) (10 mg/m2 i.v.) or V and epirubicin (E) (40 mg/m2 i.v.) every 3 weeks x 3 and every 4 weeks thereafter. Patients were stratified according to site of disease (visceral, bone or soft tissue dominant) and prior therapy. Patient groups were comparable with respect to menopausal status, age, estrogen receptor status and disease-free interval. About two-thirds of the patients presented with visceral recurrence and 30% with bone lesions: only 8% had soft tissue metastases. RESULTS We observed a significant difference (p = 0.003) in the frequency of alopecia (WHO grade 3-4, 36% vs. 60% favoring regimen VM); gastrointestinal and hematologic side effects and neurotoxicity were mild and similar for both groups. In 182 evaluable patients there was a 26% response rate (CR + PR. UICC criteria) for VM and 35% for VE (not significant). NC was observed in 37% and 43% of patients treated with VM or VE respectively. There was no significant difference between these two groups with regard to time to progression and survival. The median time of follow-up was 8 months and therefore too short to draw definite conclusions. Both regimens were well tolerated and seem to be equally effective, although the response rate for VM and VE was lower than expected.
Collapse
|
33
|
Platz H, Engleder R, Fridrik M, Hudec M, Schwarzl G. [Multimodal treatment of inoperable oral and maxillofacial squamous cell carcinoma]. Z Stomatol 1988; 85:359-70. [PMID: 3274597] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|
34
|
Becher R, Haas OA, Graeven U, Bettelheim P, Ambros P, Fridrik M, Schaefer UW, Schmidt CG. Translocation t(8;16) in acute monocytic leukemia. Cancer Genet Cytogenet 1988; 34:265-71. [PMID: 3165700 DOI: 10.1016/0165-4608(88)90271-3] [Citation(s) in RCA: 27] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
A report is given of three new cases of acute monocytic leukemia, FAB M5a, with a t(8;16)(p11;p13). Two cases showed a marked erythrophagocytosis, including one with phagocytosis of normoblasts and granulocytes. Phagocytosis was absent in the third case. The t(8;16) was the only abnormality in two cases, whereas one case showed clonal evolution with partial trisomy 1q and a deletion of part of the short arms of chromosomes 1 and 3. Treatment results and survival were poor in all cases. A complete remission was achieved in two patients, which lasted only for 3 and 6 months, respectively. In one of these cases a central nervous system relapse occurred. Survival was short, lasting between 1 and 9 months. One patient succumbed to interstitial pneumonitis, a complication of allogeneic bone marrow transplantation without evidence for relapsing leukemia.
Collapse
Affiliation(s)
- R Becher
- Innere Universitätsklinik (Tumorforschung), West German Tumor Center, Essen
| | | | | | | | | | | | | | | |
Collapse
|
35
|
Kaiser W, Biesenbach G, Fridrik M, Syre G, Zazgornik J. [Nephrotic syndrome following Hodgkin's disease]. Med Klin (Munich) 1988; 83:387-9, 390. [PMID: 3405156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|
36
|
Wahl G, Fridrik M, Seir J, Herbinger W. [Serum angiotensin-converting enzyme (SACE) in HIV infection]. Dtsch Med Wochenschr 1988; 113:278. [PMID: 2830090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
|
37
|
Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, Jagannath S, Hagemeister FB, Redman JR, Swan F. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988; 71:117-22. [PMID: 3334893] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
Ninety patients with progressive recurrent lymphoma were treated with a combination of cisplatin 100 mg/m2 intravenously (IV) by continuous infusion over 24 hours, followed by cytosine arabinoside in two pulses each at a dose of 2 g/m2 given 12 hours apart. Dexamethasone, 40 mg orally or IV, was given on days 1 through 4. Vigorous hydration was reinforced by routine use of mannitol. Treatments were repeated at 3- to 4-week intervals for six to ten courses. Most patients had not achieved complete remission (CR) with prior therapies, which included Adriamycin (all patients) and methotrexate and VP-16 (58 patients). Median patient age was 55 years. Intermediate-grade lymphoma was the most frequent pathologic diagnosis. Seven patients died within two weeks of therapy; of the remaining 83 patients, 28 (34%) or 31% if all patients are considered, achieved CR, and 22 (26.5%) achieved partial remission (PR). Response was evident after the first two cycles of chemotherapy and appeared to be independent of the histopathologic type of lymphoma. To date, only eight of the complete responders have relapsed at a median follow-up of 11 months. The overall 2-year survival in 25%. Further analysis showed that patients with low tumor burden and normal lactic acid dehydrogenase (LDH) had a high CR response rate (67%) and a survival rate of 61% at 2 years. In contrast, patients with both high tumor burden and elevated serum LDH levels had a negligible CR rate, and only 5% are surviving at 1 year. Patients with either high tumor burden with normal LDH or low tumor burden with elevated LDH had an intermediate survival. Myelosuppression-related infection was the most frequent serious complication of this regimen (31%) and the cause of death of ten patients. Acute lysis syndrome was also observed in five patients with high tumor burden and was the cause of death in three of these patients. DHAP has proven to be an effective non-crossresistant regimen for patients with relapsing or refractory lymphoma, particularly for patients who have favorable prognostic characteristics.
Collapse
Affiliation(s)
- W S Velasquez
- Department of Hematology, University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute, Houston 77030
| | | | | | | | | | | | | | | | | | | |
Collapse
|